Pyridostigmine bromide is incorporated into low-dose scored tablets for canine and feline acquired myasthenia gravis, where reversible carbamylation of the esteratic site of acetylcholinesterase slows synaptic acetylcholine hydrolysis at nicotinic motor endplates. The dosage window is narrow because excessive cholinesterase inhibition shifts the patient from improved muscle strength into muscarinic crisis marked by bradycardia, salivation, and bronchoconstriction; therefore finished dosage units in the 1 mg–10 mg range require stricter content uniformity control than higher-dose human tablets. In a representative direct-compression core with total mass of 180 mg, a 5 mg strength corresponds to 2.8% w/w pyridostigmine bromide in a carrier matrix of lactose monohydrate and microcrystalline cellulose, with colloidal silicon dioxide added at 0.5% w/w to improve hopper flow. Excipient selection is governed by the need for angle of repose below 35° and bulk density within 0.55–0.70 g/mL to reduce segregation during rotary tablet press operation. Production on an 8-station rotary press with 6 mm round concave tooling typically applies 6–9 kN compression force to produce hardness of 3–6 kp and friability under 0.8% by USP <1216>. The process sequence includes geometric dilution of API in a polyethylene bag, 10-minute blending in a V-blender at 25 RPM, and compression after humidity control below 40% RH because pyridostigmine bromide is hygroscopic. Release testing follows Ph. Eur. 2.2.29 for assay, USP <905> for content uniformity with acceptance value not more than 15.0, USP <711> for dissolution with Q 75% in 45 minutes in 0.1 N hydrochloric acid, and USP <61>/<62> for microbial limits. Residual solvents in the API are controlled under USP <467> and VICH GL18; API manufacture itself is expected to follow ICH Q7.

Why Does Aseptic Filtration Outperform Terminal Sterilisation for 2.5 mg/mL Pyridostigmine Parenterals?

Injectable formulations of pyridostigmine bromide are prepared for parenteral administration in veterinary patients that cannot tolerate oral dosing during acute myasthenic crisis or in perioperative settings where consistent systemic availability is required. The target concentration of 2.5 mg/mL in Water for Injection is adjusted to pH 4.0–5.0 with 0.1 M hydrochloric acid or 0.1 M sodium hydroxide; solutions are filled into 2 mL Type I borosilicate glass vials with chlorobutyl rubber stoppers. The manufacturing route is aseptic filtration because published stability data for pyridostigmine bromide under steam sterilization conditions are limited and the bromide salt may undergo hydrolytic degradation at elevated temperature; therefore terminal sterilization cannot be assumed. Compounding is conducted under ISO 14644-1 class 5 conditions inside an EU GMP Annex 1-compliant aseptic filling line, with a 0.45 µm PVDF pre-filter followed by two 0.22 µm polyethersulfone membranes in series. Filter integrity is verified by bubble point testing before and after filtration. Sterility testing follows USP <71>, bacterial endotoxin limits follow USP <85> at not more than 0.5 EU/mg, and particulate matter is controlled under USP <788> for small-volume injections. The preparation is considered a high-risk compounded sterile preparation under USP <797> when prepared in a pharmacy compounding facility, and beyond-use dating is therefore assigned conservatively, typically not exceeding 24 hours at room temperature or 3 days under refrigeration unless a full stability protocol validates longer storage.

Where oral liquid compounding is required for feline patients or dogs with dysphagia, the API is levigated with glycerin before incorporation into a preserved aqueous vehicle to avoid clumping of fine particles. A commonly prepared oral suspension has a concentration of 1.0 mg/mL pyridostigmine bromide in a 1:1 vehicle containing sorbitol and microcrystalline cellulose/carboxymethylcellulose sodium; the addition ratio is adjusted from a 100 mg/100 mL master formula and is not suitable for food-producing species because a maximum residue limit has not been established. High-shear mixing is performed at 1,000 rpm for 20 minutes to achieve uniform dispersion, followed by passage through a 40-mesh stainless steel screen to remove agglomerates. The suspension is filled into amber polyethylene terephthalate bottles with oral syringe adapters to reduce dosing error at bodyweight-adjusted volumes below 0.5 mL. Nonsterile preparation falls under USP <795>; accelerated stability screening at 25 °C/60% RH and 40 °C/75% RH guides beyond-use dating, which is typically limited to 14 days refrigerated for preserved aqueous vehicles in the absence of a product-specific stability study. Viscosity is measured with a Brookfield viscometer to keep the preparation pourable through the oral syringe adapter, and resuspendability is confirmed by inverting the closed container ten times at each stability pull point.

Equine Oral Granules and the Risk of Dose Non-Uniformity in Bran-Based Carriers

Published data for pyridostigmine bromide granules in equine gastrointestinal motility is limited; however, hospital formularies have used the API in extemporaneous oral granules for non-food equine patients under extralabel conditions of FDA 21 CFR 530 or the cascade in EU Regulation 2019/6. A granular carrier containing 1% w/w pyridostigmine bromide in an alfalfa-bran base is prepared by wet granulation because direct blending at that dilution produces segregation and poor adherence to fibrous carriers. The manufacturing process adds a 2% w/w povidone K30 binder solution, granulates in a high-shear mixer at impeller speed 300 rpm, and dries in a fluid-bed dryer at 40 °C until loss on drying is below 2.0%. The dried granules are sieved between 500 µm and 1.0 mm, and oversized material is milled through a conical mill at 1,500 rpm to narrow particle-size distribution. Content uniformity of the granule fraction is tested on 10 randomly drawn units by Ph. Eur. 2.2.29; a relative standard deviation over 5.0% indicates inadequate binder distribution or insufficient wet massing time. Finished oral granules are packaged in foil-lined sacks or single-dose syringes as an oral granule, not as a licensed premix for food-producing horses; slaughter withdrawal intervals cannot be assigned because no maximum residue limit exists.

Water-Soluble Premix for Non-Food Species Under Extralabel Cascade Conditions

Pyridostigmine bromide is not approved as a feed additive in the European Union, United States, or United Kingdom, and no maximum residue limit has been established for food-producing animals; therefore water-soluble premixes are confined to non-food species such as companion exotic mammals or zoological collections under veterinary extralabel discretion. A 1% w/w water-soluble premix in lactose monohydrate is used as a stock powder that is diluted at 0.25–1.0 g/L in drinking water to achieve approximate bodyweight-adjusted delivery, but published dose validation for this specific configuration is limited and fluid consumption must be monitored. Blending is performed by geometric dilution in a 100 L V-blender at 20 rpm for 15 minutes under relative humidity below 30% RH, and 0.2% w/w colloidal silicon dioxide is included to reduce caking. The final premix is filled into aluminium foil sachets under nitrogen flush because the bromide salt is hygroscopic. Quality control follows USP <795> for nonsterile compounding, USP <467> for residual solvents, and Ph. Eur. 2.2.29 for assay; extended storage beyond 30 days requires a dedicated stability protocol.

Capsule compounding of pyridostigmine bromide in the 0.5–5.0 mg fill range is used when tablet splitting creates unacceptable dose inaccuracy in dogs and cats under 10 kg bodyweight or when a gelatin-free capsule is required for patient-specific dietary reasons. A representative 1.0 mg strength in a size 3 hypromellose capsule is produced by geometric dilution of milled API with microcrystalline cellulose to a total fill mass of 100 mg, giving 1.0% w/w active content. Powder flow for semi-automatic capsule filling is evaluated by USP <1174>; angle of repose above 40° or compressibility index above 25% indicates that a granulation step is required before filling. On a 100-hole manual capsule machine, fill weight variation is controlled within ±10% for the 1.0 mg strength, and in-process checks are taken every 30 minutes. Finished capsules are dedusted, visually inspected, and packaged in amber high-density polyethylene bottles with desiccant. Beyond-use dating follows USP <795> guidance; in the absence of product-specific stability data, the beyond-use date should not exceed 180 days for dry oral capsules stored at controlled room temperature.